Latest European Commission guidance on ‘no deal’ Brexit
On 13 November, the European Commission issued its latest advice on preparations across the EU for the possibility of a ‘no-deal’ Brexit.
The Commission set out several key industries deemed necessary for special, temporary contingency plans to avoid turmoil at borders, at airports and elsewhere. That didn’t include health care, despite concerns having been raised about possible disruption to medicines supply.
Instead, the Commission reminded businesses the buck stops with them to prepare for the worst-case scenario. “Contingency measures taken by national or EU authorities cannot replace the preparations that each citizen and business must take to prepare for the United Kingdom’s withdrawal,” the guidance said. “Where new authorizations, licences or certificates will be required, each party has the responsibility to apply in good time,” it added.
Regarding medicines, the guidance noted: “The European Medicines Agency (EMA) has conducted several surveys and, where necessary, has contacted holders of EU marketing authorizations to recall the need to take the necessary preparedness measures.” Together with the European Chemicals Agency (ECHA), and others, the EMA has re-attributed regulatory functions from the U.K. to other member countries, it added.
In the event of a no deal, all relevant EU legislation on imported goods and exported goods will apply, “including the levy of certain duties and taxes (such as customs duties, value added tax and excise on importation), in accordance with the commitments of the European Union under the rules of the World Trade Organisation,” the Commission states.
|Read the full report here|
NPA members with questions or concerns relating to Brexit should contact the NPA Pharmacy Services team on 01727 891 800 or email email@example.com